Covovax Covid-19 Vaccine
- All
- News
- Videos
-
Current Covid Strain Mild, 5-6 Million Covovax Doses Made: Adar Poonawalla
The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.
-
China Needs "Good Covid Booster" Like Covovax, Says Adar Poonawalla
China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.
-
Serum Institute's Covid Vaccine Covovax Cleared For 7-11 Age Group
The Drugs Controller General of India (DCGI) on Tuesday approved Serum Institute's COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions, official sources said.
-
"Covovax Available For Everyone Above 12 Years", Tweets Adar Poonawalla
Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.
-
Covovax Vaccine Now Available For 12-17 Age Group At Private Centres
Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.
-
Immunisation Panel Approves Covovax Vaccine For 12-17 Age Group: Report
National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.
-
COVID-19 Working Group To Review Data For Covovax Vaccine On Friday: Report
The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.
-
Influential US Congress Members Urge Vaccine Collaboration With India
Members of America's influential Congressional Hispanic Caucus have urged US President Joe Biden to champion vaccine collaboration with India to bring an end to the COVID-19 pandemic.
-
Covovax Gets Emergency Use Approval For Children Above 12 Years
India's drug regulator has granted restricted emergency use authorisation to Serum Institute of India's COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions, official sources said on Wednesday.
-
Serum Institute Seeks Nod For Phase-3 Study Of Covovax As Booster Dose In Adults
Serum Institute of India has sought permission from India's drug regulator to conduct a phase-3 study of its COVID-19 vaccine Covovax as a booster dose in adults, official sources said on Sunday.
-
Serum Institute Seeks Emergency Use Approval Of Covid Vaccine Covovax In South Africa
Novavax and Serum Institute of India (SII) announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization (EUA) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine
-
Serum Institute Thanks Centre For Emergency Use Approval For Covovax
Serum Institute of India on Tuesday expressed gratitude to the Union Health Ministry for granting Emergency Use Authorization for its COVID-19 vaccine Covovax.
-
India Clears 2 New Vaccines And Merck's Covid Pill: 10 Points
The centre cleared two more vaccines today and one anti-viral drug to boost the fight against the COVID-19 pandemic. The two latest vaccines cleared by India are Corbevax and Covovax. The anti-viral drug Molnupiravir can be used during emergency.
-
Serum Institute Seeks Drug Regulator's Approval For Covovax Vaccine: Report
The Serum Institute of India on Friday sought permission from the Drugs Controller General of India (DCGI) to manufacture COVID-19 vaccine Covovax for restricted use in emergency situations at its Manjari manufacturing site, official sources said.
-
Recruitment Of Volunteers For Trial Of Covovax Vaccine On Children Begins
Recruitment of volunteers for the phase 2/3 clinical trial of COVID-19 vaccine Covovax among children aged 2 to 17 years began on Sunday at the Hamdard Institute of Medical Sciences and Research In Delhi.
-
Current Covid Strain Mild, 5-6 Million Covovax Doses Made: Adar Poonawalla
The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.
-
China Needs "Good Covid Booster" Like Covovax, Says Adar Poonawalla
China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.
-
Serum Institute's Covid Vaccine Covovax Cleared For 7-11 Age Group
The Drugs Controller General of India (DCGI) on Tuesday approved Serum Institute's COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions, official sources said.
-
"Covovax Available For Everyone Above 12 Years", Tweets Adar Poonawalla
Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.
-
Covovax Vaccine Now Available For 12-17 Age Group At Private Centres
Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.
-
Immunisation Panel Approves Covovax Vaccine For 12-17 Age Group: Report
National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.
-
COVID-19 Working Group To Review Data For Covovax Vaccine On Friday: Report
The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.
-
Influential US Congress Members Urge Vaccine Collaboration With India
Members of America's influential Congressional Hispanic Caucus have urged US President Joe Biden to champion vaccine collaboration with India to bring an end to the COVID-19 pandemic.
-
Covovax Gets Emergency Use Approval For Children Above 12 Years
India's drug regulator has granted restricted emergency use authorisation to Serum Institute of India's COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions, official sources said on Wednesday.
-
Serum Institute Seeks Nod For Phase-3 Study Of Covovax As Booster Dose In Adults
Serum Institute of India has sought permission from India's drug regulator to conduct a phase-3 study of its COVID-19 vaccine Covovax as a booster dose in adults, official sources said on Sunday.
-
Serum Institute Seeks Emergency Use Approval Of Covid Vaccine Covovax In South Africa
Novavax and Serum Institute of India (SII) announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization (EUA) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine
-
Serum Institute Thanks Centre For Emergency Use Approval For Covovax
Serum Institute of India on Tuesday expressed gratitude to the Union Health Ministry for granting Emergency Use Authorization for its COVID-19 vaccine Covovax.
-
India Clears 2 New Vaccines And Merck's Covid Pill: 10 Points
The centre cleared two more vaccines today and one anti-viral drug to boost the fight against the COVID-19 pandemic. The two latest vaccines cleared by India are Corbevax and Covovax. The anti-viral drug Molnupiravir can be used during emergency.
-
Serum Institute Seeks Drug Regulator's Approval For Covovax Vaccine: Report
The Serum Institute of India on Friday sought permission from the Drugs Controller General of India (DCGI) to manufacture COVID-19 vaccine Covovax for restricted use in emergency situations at its Manjari manufacturing site, official sources said.
-
Recruitment Of Volunteers For Trial Of Covovax Vaccine On Children Begins
Recruitment of volunteers for the phase 2/3 clinical trial of COVID-19 vaccine Covovax among children aged 2 to 17 years began on Sunday at the Hamdard Institute of Medical Sciences and Research In Delhi.
